CAJ | 학술논문

目的评价奥氮平、齐拉西酮治疗精神分裂症的疗效和安全性.方法将60例精神分裂症急性发作的患者随机分为奥氮平组(n=30)、齐拉西酮组(n=30),分别给予奥氮平、齐拉西酮单药治疗6周.在治疗前及治疗后第2、4、6周末采用阳性阴性症状量表(PANSS)评定其疗效、副反应量表(TESS)评定其不良反应.结果治疗后2周奥氮平组PANSS总分显著下降(P<0.01),治疗后4、6周各组的PANSS总分均有显著下降(P<0.01).奥氮平组的主要不良反应为嗜睡、便秘、体重增加及肝功能异常;齐拉西酮组的主要不良反应为锥体外系不良反应(EPS)、嗜睡、兴奋激越.结论奥氮平、齐拉西酮治疗精神分裂症急性发作的疗效相当,但奥氮平起效较快,两种药物不良反应总体较轻.
목적평개오담평、제랍서동치료정신분렬증적료효화안전성.방법장60례정신분렬증급성발작적환자수궤분위오담평조(n=30)、제랍서동조(n=30),분별급여오담평、제랍서동단약치료6주.재치료전급치료후제2、4、6주말채용양성음성증상량표(PANSS)평정기료효、부반응량표(TESS)평정기불량반응.결과치료후2주오담평조PANSS총분현저하강(P<0.01),치료후4、6주각조적PANSS총분균유현저하강(P<0.01).오담평조적주요불량반응위기수、편비、체중증가급간공능이상;제랍서동조적주요불량반응위추체외계불량반응(EPS)、기수、흥강격월.결론오담평、제랍서동치료정신분렬증급성발작적료효상당,단오담평기효교쾌,량충약물불량반응총체교경.
[Abstrct]objective The study was designed to evaluate the efficacy and safety of olanzapine and ziprasidone in hospitalized patients with acute-episode schizophrenia. Methods 60 patients with CCMD-3 schizophrenia were randomized into olanzapine group (n=30) and ziprasidone group (n=30) treatment in a 6-week paralel-group study. The efficacy and side effects were assessed with the Positive and Negative Syndrome Scale (PANSS) ,Treatment Emergent Symptom Scale (TESS) at the end of the 2nd, 4th and 6th week of treatment. Results Olanzapine group demonstrated a significant decrease in PANSS score (P<0.01) at the end of 2nd week of treatment. Olanzapine group and ziprasidone group had a significant decrease in PANSS score at the end of 4th and 6th week of treatment. (P<0.01) . The common adverse events were somnolence, constipation, abnormal liver function and body weight increasing in olanzapine group, and extrapyremidal symptoms, somnolence, excitement and agitation in ziprasidone group. Conclusion Olanzapine and ziprasidone are similarly effective in significantly improving the symptoms in patients with acute-episode schizophrenia. The onset of the action of olanzapine is fast compared with that of ziprasidone. The adverse drug reaction of the two atypical antipsychotics is less in general.